Overview

Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Status:
Completed

Trial end date:
2016-09-19

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare the progression-free survival of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) treated with VTX-2337 + cisplatin or carboplatin + 5-FU + cetuximab versus patients treated with cisplatin or carboplatin + 5-FU + cetuximab alone (standard-of-care; SOC). Safety and overall survival will also be evaluated.

Phase:

Phase 2

Details

Lead Sponsor:

Celgene
VentiRx Pharmaceuticals Inc.

Treatments:

Carboplatin
Cetuximab
Cisplatin
Fluorouracil